Antengene announces inclusion of xpovio® (selinexor) in 2023 china's national reimbursement drug list

Shanghai and hong kong , dec. 13, 2023 /prnewswire/ -- antengene corporation limited ("antengene" sehk: 6996.hk), a leading innovative, commercial-stage global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for cancer, today announced that xpovio® (selinexor) has been added to the national reimbursement drug list (2023 version) ("nrdl") for the treatment of adult patients with relapsed or refractory multiple myeloma (r/r mm) whose disease is refractory to at least one proteasome inhibitors (pis), one immunomodulatory agent (imid), and an anti-cd38 monoclonal antibody (mab). the updated nrdl will officially take effect on january 1, 2024.
KPTI Ratings Summary
KPTI Quant Ranking